“…Originally, ODDD was thought to be exclusively a disease linked to autosomal dominant mutations which would allow for the possibility that the allele harboring the wild-type gene could suffice to provide sufficient Cx43-based GJIC and allow patients to maintain essential organ function as seems to be the case in the heart where Cx43 is abundant (Gros and Jongsma, 1996). Many of these autosomal dominant mutants have been categorized by us and others as loss-of-function mutants, gain-of-hemichannel function mutants or dominant-negative mutants on co-expressed wild-type Cx43 (Churko et al, 2011a;Churko et al, 2012;Churko et al, 2010;Churko et al, 2011b;Dobrowolski et al, 2009;Dobrowolski et al, 2008;Dobrowolski et al, 2007;Flenniken et al, 2005;Gong et al, 2007;Gong et al, 2006;Lai et al, 2006;Langlois et al, 2007;Lorentz et al, 2012;Manias et al, 2008;McLachlan et al, 2005;McLachlan et al, 2008;Musa et al, 2009;Shao et al, 2012;Shibayama et al, 2005;Stewart et al, 2013;Toth et al, 2010). However, our understanding of the characteristics of Cx43 mutants became more complicated when two autosomal recessive mutations were identified that encoded a severely truncated Cx43 (R33X) (Richardson et al, 2006) and an arginine to a histidine (R76H) substitution within the domain predicted to be at the extreme region of the 1st extracellular loop (Pizzuti et al, 2004).…”